Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Pharmaceutical Excipients Market To Reach USD 10.15 Billion By 2027

Published

on

New York, April 01, 2020 (GLOBE NEWSWIRE) — According to the current analysis of Reports and Data, the global Pharmaceutical Excipients Market valued at USD 6.53 billion in 2019 and is expected to reach USD 10.15 billion by the year 2027, at a CAGR of 5.7%. Excipients are the products that do not show any activity of the drug but facilitates the drug delivery process. The increase in the outbreak of pandemic or epidemic diseases across the globe is the primary factor for boosting the growth of the market. The problems associated with instability, poor solubility, and absorption of active pharmaceutical ingredients are driving the demand for pharmaceutical excipients. The development of nanotechnology for the administration of drugs is further boosting the growth of the market. In 2015, the amount of manufacturing of final products of drugs in Japan accounted for 6,820.4 billion yen, the amount of import was 4,022 billion yen. Increasing outbreak of life threatening diseases and increasing incidences of resistance over traditional treatment plan resulting in increasing number of final production are expected to boost the market growth.
North America has obtained remarkable growth in the market due to the awareness among the consumers for better healthcare, government initiatives for research and development of new drugs, clinical trials, and due to better facilities for healthcare in the region. However, the high cost of drug development is the primary restraint to market growth.Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/2713The COVID-19 Impact: The sudden outbreak of COVID-19 has reported significant growth in the pharmaceutical excipients market. According to the recent epidemiological data the fight against COVID-19 is expected to continue furthermore for some considerable time, especially in Europe. Pharmaceutical companies are engaged in developing the appropriate and desired treatment plan or medicines. Increasing production of final products in the industry has gained huge demand of excipients required for the formulation. However, it might impact negatively to emerging nations in Asia such as China and India, due to the increased restrictions towards international trade i.e., export or import. In such circumstances, companies especially in US and Europe have shifted towards manufacturer from the same state or backward expansion strategies, i.e., companies are owning their own excipients manufacturing plants. For instance, ReForm Biologics, a pharmaceutical technology company and MilliporeSigma have entered an agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. Certain excipients have been established high acceptance for manufacturing drug for COVID-19 treatment for example, hydroxypropyl beta-cyclodextrins (HPβCD) it acts as functional excipient. Certain bodies are also playing vital role in market impact of COVID-19 outbreak. EXCiPACT updated position paper on COVID-19 (Coronavirus) EXCiPACT asbl is a non-profit organisation that require excipient users to qualify their suppliers based on GMP/GDP audits. It regulates such an independent, high quality, third party Certification Scheme available to pharmaceutical excipient manufacturers and distributors worldwide.Further key findings from the report suggestEvonik in the year 2017 had launched a new sterile, and ultra-low-metal content bioresorbable polymers known as RESOMER ZERO it is an ultra-low tin content PLGA poly (lactic-co-glycolic acid) excipient and is the first sterile controlled release (PLGA) excipient in the market. It was designed for the controlled-release parenteral drug formulation.Croda International, in the year 2018 had launched Moonshine Effect Pigments, it is a range of borosilicate-based effect pigments, it is specially designed for personal care products, the quality borosilicate substrate produces the effect exceptional vibrancy, intensity, and color transmission for eye-catching results in cosmetic formulations.JRS Pharma had received an EXCiPACT Certificate from DQS for the production of Microcrystalline Cellulose and Silicified Microcrystalline Cellulose and for Good Distribution Practice for the central logistic warehouse. The certificate justifies that the Micro cellulose is manufactured and distributed according to the EXCiPACT Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certification Standard. The certificate is beneficial for the drug manufacturers to reduce their efforts and costs for performing quality control.Oral formulations in the formulations segment have obtained the largest share due to the rise in demand for formulations like tablets, capsules, and oral solutions and suspensions. It is likely to grow with a CAGR of 5.9% in the forecast period.Ashland Global Holdings (US), BASF SE (Germany), DuPont (US), Roquette Feres (France), Evonik Industries AG (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), Croda International (UK). Innophous Holdings (US), Kerry Group (Ireland), WACKER Chemie AG (Germany), Colorcon (US), DFE Pharma (Germany), JRS Pharma (Germany), and Air Liquide (France) are the key players in the Pharmaceutical Excipients marketBUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/2713For this purpose, Reports and Data have segmented the Pharmaceutical Excipients market on the basis of products, functionality, formulations, end use, and region. Products Outlook (Revenue in Million USD; (2017–2027)Organic ChemicalsOleochemicalsFatty AlcoholsMineral StearatesGlycerinOther OleochemicalsCarbohydratesSugarsActual SugarsLactoseSucroseDextrose (D-Glucose)Sugar AlcoholsMannitolSorbitolOther Sugar AlcoholsArtificial SweetenersCelluloseMicrocrystalline CelluloseCellulose EthersCMC and Croscarmellose SodiumCellulose EstersStarchModified StarchDried StarchConverted StarchPetrochemicalsGlycolsPolyethylene GlycolPropylene GlycolPovidonesMineral HydrocarbonsPetrolatumMineral WaxesMineral OilsAcrylic PolymersOther PetrochemicalsProteinsOther Organic ChemicalsInorganic ChemicalsCalcium PhosphateMetal OxidesHalitesCalcium CarbonateCalcium SulfateOther Inorganic ChemicalsOthersPharmaceutical-Grade Water MucilageFunctionality Outlook (Revenue in Million USD; (2017–2027)Fillers and DiluentsSuspending and Viscosity AgentsCoating AgentsBindersFlavouring Agents and SweetenersDisintegratesColorantsLubricants and GlidantsPreservativesEmulsifying AgentsOthersFormulations Outlook (Revenue in Million USD; (2017–2027)Oral FormulationsTabletsCapsulesHard Gelatin CapsulesSoft Gelatin CapsulesLiquid FormulationsTopical FormulationsParenteral FormulationsOthersEnd Use Outlook (Revenue in Million USD; (2017–2027)Pharmaceutical companiesChemical companiesOthersRegional Outlook (Revenue in Million USD; (2017–2027)North AmericaU.SCanadaEuropeGermanyFranceUKSpainItalyRest of the EuropeAsia PacificChinaIndiaJapanRest of Asia-PacificMiddle East & AfricaLatin AmericaBrazilTo identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/pharmaceutical-excipients-marketAbout Reports and DataReports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: [email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

First Comprehensive Report on Public Web Data Released by Bright Data

Published

on

first-comprehensive-report-on-public-web-data-released-by-bright-data

Reveals necessity in every industry
NEW YORK, April 23, 2024 /PRNewswire/ — Released today, The State of Public Web Data Report 2024, details a comprehensive analysis on how organizations leverage public web data to drive innovation, enhance customer experience, and develop AI models.

Bright Data commissioned an independent third-party to carry out the first survey of this kind which details the emergence of public web data as the most valued data type. Nearly every organization surveyed uses and benefits from public web data through quicker decision-making, boosting revenue, and meeting customer needs.
The need for public web data in AI is clear in all industries, with more than half of respondents using public web data to build AI models for customer service or to meet internal needs such as fraud detection and risk assessment.
Although necessary to build AI machines, 72% of respondents are worried that public web data will no longer be accessible in the next 5 years. The lack of a legal framework to protect this data emerged as a top concern.
Other key insights from the report:
89% of respondents recognize public web data is crucial or very important to the global economy.82% of respondents say public web data is critical to the future of their organization.79% of respondents agree that large organizations and or big tech hide too much of their public web data.88% of respondents believe public web data is critical for the development of AI models.”Our findings reveal a clear consensus among industry leaders: leveraging public web data is key to unlocking growth and fostering innovation,” said Or Lenchner, CEO of Bright Data. “Public web data is not a ‘like to have,’ it’s a ‘must have’ to conduct business and maintain a competitive market. We understand from our own experience with 20,000 customers that once a business realizes the potential of public web data they will look to discover new ways to leverage this tool to lead against the competition.”
About Bright Data: Bright Data is the #1 web data platform. Fortune 500 companies, academic institutions, non-profits, and small businesses rely on Bright Data’s solutions to collect public web data in the most efficient, reliable, and flexible way to make faster, more informed business-critical decisions.
Contacts:[email protected]
Logo – https://mma.prnewswire.com/media/2276620/Bright_Data_logo__1044x234_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/first-comprehensive-report-on-public-web-data-released-by-bright-data-302124673.html

Continue Reading

Artificial Intelligence

OSIA becomes an official International Telecoms Union (ITU) standard

Published

on

osia-becomes-an-official-international-telecoms-union-(itu)-standard

ITU Standardization Sector (ITU-T) Recommendation X.1281 – APIs for interoperability of identity management systems
BRUSSELS, April 23, 2024 /PRNewswire/ — The Secure Identity Alliance (SIA) announced today that its OSIA specification, is recognized as international standard by the International Telecommunication Union’s Telecommunication Standardization Sector (ITU-T). This milestone establishes OSIA as official ITU standard (ITU-T Recommendation) for the global infrastructure of information and communication technologies (ICT).

The specification that is now an ITU-T Recommendation is: ITU-T X.1281 – APIs for interoperability of identity management systems.
ITU-T is the standardization arm of ITU, the United Nations specialized agency for ICT. The Secure Identity Alliance specifications were approved as official ITU-T Recommendations by ITU members including 193 countries and the world’s front-running ICT companies on 1st March 2024. The new ITU-T Recommendation is under the responsibility of ITU’s standardization expert group for security, ITU-T Study Group 17.
“We are very proud that the OSIA specification is recognized as an international standard by ITU-T. This milestone demonstrates the maturity of OSIA and its potential to foster interoperability and promote fairness in the identity management systems market,” said Debora Comparin, Chair of the OSIA Initiative.
Prof. Heung Youl Youm, Chairman of ITU-T Study Group 17, said, “The recognition of the OSIA specification as an official ITU-T Recommendation underscores its critical contribution to the advancement of global ICT infrastructure. We are thrilled about the ongoing collaboration between ITU-T SG17 and the SIA, aimed at developing standards for secure identity management.”
“As Editor of the OSIA standard in the ITU-T Study Group 17 Q10, I am pleased to have contributed to this successful recommendation by the ITU,” said Abbie Barbir, Rapporteur for ITU-T’s working group on ‘Identity management and telebiometrics architecture and mechanisms’ (Q10/17). “The collaboration with the SIA continues on OSIA and other structuring initiatives and standards development.”
Engr Abisoye Coker-Odusote, CEO, National Identity Management Commission (NIMC), Nigeria & Chair of the OSIA Advisory Committee, said, “As the Chair of the OSIA Advisory Committee, comprised exclusively of government representatives, we take great pride in our five years of collaboration guiding the working group in the development of the OSIA specification. OSIA establishes equal marketplace conditions, fosters collaboration, and ensures product compatibility post-mergers and acquisitions. The OSIA standardized interfaces drive innovation, enabling new local market models and reducing fraud within multiple ID systems. Additionally, OSIA addresses integrator/vendor lock-in, allowing governments to maintain control over their identity systems and pursue national development agendas seamlessly.”
“The Secure Identity Alliance has always supported standards and its members have contributed to thousands of standards globally, which are now used in the ICT market. Standards are key to unlock the full power of Identity to enable people, economy and society to thrive,” concluded Didier Trutt, Chairman of the SIA.
X.1281 is at publication stage and can be accessed here: https://www.itu.int/ITU-T/workprog/wp_item.aspx?isn=18778
OSIA v6.1.0. twin specification can be accessed here: https://osia.readthedocs.io/en/v6.1.0/index.html 
OSIA qualification programme can be accessed here: https://globalplatform.org/osia-qualification-program/
For more information on the Secure Identity Alliance and the OSIA Initiative, visit http://www.secureidentityalliance.org and www.osia.io
For more information on ITU-T SG 17 visit https://www.itu.int/en/ITU-T/studygroups/2022-2024/17/Pages/default.aspx.
About the Secure Identity Alliance:
Secure Identity Alliance (SIA) is a global non-profit association that serves as the voice for public and private actors and organizations active in the secure identity ecosystem and adjacent industries. SIA’s mission is to unlock the full power of identity so that people, economy, and society thrive. The association supports the development of the activities of its members across four broad pillars: Identity for Good, Outreach, Open Standards Development and Industry Services and Solutions. www.secureidentityalliance.org
About OSIA:
A digital public good, OSIA is an open standard set of interfaces (APIs) that enables seamless connectivity between building blocks of the identity management ecosystem – independent of technology, solution architecture or vendor.  More information at www.osia.io
Follow the Secure Identity Alliance at on X @secureidentity1 and LinkedIn at https://www.linkedin.com/company/secure-identity-alliance/ 
About ITU-T SG 17
The ITU Telecommunication Standardization Sector (ITU-T) is one of the three Sectors (branches) of the International Telecommunication Union (ITU). It is responsible for coordinating standards for telecommunications and Information Communication Technology such as X.509 for cybersecurity, Y.3172 and Y.3173 for machine learning, and H.264/MPEG-4 AVC for video compression, between its Member States, Private Sector Members, and Academia Members.
Logo: https://mma.prnewswire.com/media/2394623/OSIA_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/osia-becomes-an-official-international-telecoms-union-itu-standard-302124668.html

Continue Reading

Artificial Intelligence

SciBase will present at the Redeye Medtech Event on April 24th

Published

on

scibase-will-present-at-the-redeye-medtech-event-on-april-24th

STOCKHOLM, April 23, 2024 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders will participate at the Redeye Medtech event.

On April 24 at CET 9.50 CEO Pia Renaudin will present the latest developments in SciBase at Redeye. The presentation is live broadcasted and can be followed at https://www.redeye.se/events/974326/redeye-theme-medtech-2 where the replay and the presentations will be available afterwards.
For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):Vator SecuritiesTel: +46 8 580 065 99Email: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/scibase-will-present-at-the-redeye-medtech-event-on-april-24-th-,c3966053
The following files are available for download:
https://mb.cision.com/Main/12371/3966053/2751965.pdf
Redeye presentation
 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-will-present-at-the-redeye-medtech-event-on-april-24th-302124656.html

Continue Reading

Trending